Compare WEC & WST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WEC | WST |
|---|---|---|
| Founded | 1896 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Power Generation | Medical/Dental Instruments |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.8B | 27.9B |
| IPO Year | 1995 | 2004 |
| Metric | WEC | WST |
|---|---|---|
| Price | $117.80 | $416.38 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 20 | 16 |
| Target Price | $118.50 | ★ $471.00 |
| AVG Volume (30 Days) | ★ 2.9M | 692.3K |
| Earning Date | 10-29-2026 | 10-29-2026 |
| Dividend Yield | ★ 3.24% | 0.25% |
| EPS Growth | N/A | ★ 1.49 |
| EPS | 4.81 | ★ 7.09 |
| Revenue | ★ $9,800,100,000.00 | $2,886,900,000.00 |
| Revenue This Year | $5.24 | $11.26 |
| Revenue Next Year | $6.03 | $5.92 |
| P/E Ratio | ★ $24.44 | $58.03 |
| Revenue Growth | ★ 13.96 | 1.95 |
| 52 Week Low | $99.80 | $223.83 |
| 52 Week High | $120.15 | $438.27 |
| Indicator | WEC | WST |
|---|---|---|
| Relative Strength Index (RSI) | 67.69 | 65.72 |
| Support Level | $110.16 | $386.88 |
| Resistance Level | $118.91 | $438.27 |
| Average True Range (ATR) | 1.99 | 11.84 |
| MACD | 0.05 | -0.12 |
| Stochastic Oscillator | 75.23 | 56.80 |
WEC Energy Group's electric and gas utility businesses serve electric and gas customers in Illinois, Michigan, Minnesota, and Wisconsin service territories. The company also owns a 60% stake in American Transmission Co. WEC's asset mix is approximately 49% electric generation and distribution, 30% gas distribution, 10% electric transmission, 9% unregulated renewable energy, and 2% LNG distribution and generation.
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.